Scarica l'app Stockscreener
9.42
3.40%
0.31
Dopo l'orario di chiusura:
9.52
0.10
+1.06%
10 X Genomics Inc Borsa (TXG) Ultime notizie
Forecasting The Future: 7 Analyst Projections For 10x Genomics - Benzinga
Long Read Sequencing Market Key Players Analysis10X Genomics, - openPR.com
10x Genomics, Inc. (NASDAQ:TXG) Stock Holdings Increased by Deutsche Bank AG - Defense World
ARK Investment Acquires 290K Shares of 10x Genomics (TXG) | TXG Stock News - GuruFocus
10x Genomics, Inc. (TXG) Stock Analysis: Evaluating the 31.90% Potential Upside - DirectorsTalk Interviews
Cathie Wood's ARK Investment Acquires Significant Stake in 10x G - GuruFocus
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARK Investment Acquires 342K Shares of 10x Genomics (TXG) | TXG Stock News - GuruFocus
Cetera Investment Advisers Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com
10x Genomics, Inc. (NASDAQ:TXG) Given Average Recommendation of “Hold” by Analysts - Defense World
Powell, Mayville Engineering, Graham Corporation, Hyster-Yale Materials Handling, and 10x Genomics Shares Skyrocket, What You Need To Know - Yahoo Finance
Shareholders May Be Wary Of Increasing 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation Package - simplywall.st
10x Genomics, Inc. (TXG) Stock Analysis: A 52.56% Potential Upside Amidst a Challenging Market - DirectorsTalk Interviews
10x Genomics’ (TXG) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Bank of America Corp DE - Defense World
Why 10x Genomics Stock Was Sliding This Week - Barchart.com
10x Genomics Reports Third Quarter 2023 Financial Results - Seeking Alpha
10x Genomics Reports First Quarter 2024 Financial Results - Seeking Alpha
Gotham Asset Management LLC Takes $264,000 Position in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
10x Genomics (NASDAQ:TXG) Price Target Lowered to $18.00 at Morgan Stanley - Defense World
10x Genomics (NASDAQ:TXG) Shares Down 4.8% Following Analyst Downgrade - Defense World
High-Throughput Transcriptomics 2025–2028: Next-Gen Breakthroughs Set to Disrupt Genomics Market - macnifico.pt
10x Genomics (TXG) Price Target Lowered by Morgan Stanley | TXG Stock News - GuruFocus
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Northern Trust Corp - Defense World
Stephens Reaffirms Overweight Rating for 10x Genomics (NASDAQ:TXG) - Defense World
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
Dimensional Fund Advisors LP Sells 23,956 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Announces Patent Litigation Settlement Agreement with Bruker - Financial Times
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Bruker and 10x Genomics settle patent dispute - Yahoo Finance
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Challenges | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
10x Genomics (TXG) Price Target Lowered by Canaccord Genuity | T - GuruFocus
Analyst Expectations For 10x Genomics's Future - Benzinga
Goldman Sachs Lowers Price Target for 10x Genomics (TXG) | TXG S - GuruFocus
JPMorgan Chase & Co. Cuts 10x Genomics (NASDAQ:TXG) Price Target to $9.00 - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
0.51%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):